Next Generation Sequencing (NGS), which is becoming more widely known as comprehensive genomic profiling by massively parallel sequencing (CGP), is set to significantly contribute to targeted therapy prescribing and complement other testing methods by 2020. Many genes are analysed simultaneously and it has the potential to detect all mutations in a patient specimen. However, the speed and spread of NGS uptake are not likely to facilitate a revolution in cancer care in this timeframe.
There are also other ‘barriers’ acting to slow or prevent the integration of NGS/CGP with diagnostic testing. Here we identify these barriers, but also point out the key drivers that can help break through them on the road to accelerated diffusion of these novel technologies into routine patient management.
1. Barriers to widespread platform and test availability: NGS/CGP diffusion is currently limited to key cancer and reference labs
2. Barriers to easy access and reimbursement: The cost of NGS/CGP testing and interpretation will remain high relative to other testing methods, until 2020+, so pharma/patient subsidy is required for targeted treatment
3. Barriers to clear clinical utility and actionable results: Clinical utility for NGS/CGP will be driven by disease-level studies
4. Barriers to new guideline recommendations: NGS/CGP guidelines and recommendations will be key but driven regionally and at a disease level
5. Barriers to optimized investment in education, real world studies and awareness to drive demand: Education requires significant financial investment
Far too many patients are currently missing out on treatment opportunities as diagnostic testing is not generally optimized and is usually under-resourced. NGS/CGP is becoming integral to diagnostic testing and the improvement of patient outcomes. When we focus on the patient, we can see more clearly what action is needed and these endpoints can be seen as ‘drivers,’ breaking through the barriers. Whether in the US and Europe or developing world markets, the diffusion of NGS/CGP for diagnostic testing and improved patient treatment will depend upon smart investment in these key drivers:
It’s often easier to identify the problem than the solution, but Diaceutics has comprehensive Services in place to help support and guide the commercialization of your diagnostic, whichever platform it requires, all helping to revolutionize patient testing.
In our webinar on 29 June 2017, Moving beyond the hype: the reality of NGS in oncology today and in the future, we will explore these and other pertinent topics regarding the potential solutions to these barriers.